Senzime Bilan de santé

Santé financière contrôle des critères 4/6

Senzime possède un total de capitaux propres de SEK285.0M et une dette totale de SEK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont SEK355.2M et de SEK70.2M.

Informations clés

Ratio d'endettement

SEK 0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 50.24m
Fonds propres	SEK 285.04m
Total du passif	SEK 70.21m
Total des actifs	SEK 355.25m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de SNZZ.F ( SEK98.2M ) dépassent ses passifs à court terme ( SEK27.6M ).

Passif à long terme: Les actifs à court terme de SNZZ.F ( SEK98.2M ) dépassent ses passifs à long terme ( SEK42.6M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: SNZZ.F est sans dette.

Réduire la dette: SNZZ.F n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: SNZZ.F dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: SNZZ.F dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 30 % chaque année

Senzime Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Senzime AB (publ) to Report Q1, 2025 Results on May 07, 2025

Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024

Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 Conference

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Senzime AB (publ) Announces Board Changes

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

Senzime Receives Approval for Its Pediatric Sensor in Japan

Senzime AB (publ) to Report Q1, 2023 Results on May 05, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Senzime AB (publ) Provides Earnings Guidance for 2025

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

Senzime AB (publ) Gets US Patent for OnZurf Probe

Senzime Lands New Order from South Korea of SEK 1 Million

Senzime AB (publ) Announces Nomination Committee for 2021 Annual General Meeting

Senzime AB (Publ) Signs an Out-Licensing Agreement with the Moss S.P.A

Senzime AB (publ) Enters into an Exclusive Agreement with the Surgical Company

Senzime AB (Publ) Announces Management Changes

Senzime AB (publ) Receives Order from Switzerland

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines